The spectrum of thrombin in acute coronary syndromes

Thrombosis Research

Volumn 135, Issue 5, 2015, Pages 782-787

  Giri, Smith ^a   Jennings, Lisa K ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute coronary syndromes; Anti platelet therapy; Anticoagulants; Coagulation; Endothelial cells; Platelets; Thrombin

Indexed keywords

THROMBIN; THROMBIN INHIBITOR; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; PROTEASE-ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ATHEROGENESIS; CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SECONDARY PREVENTION; SUBSTITUTION THERAPY; ANIMAL; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASES; CHEMISTRY; CLINICAL TRIAL (TOPIC); INFLAMMATION; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RISK FACTOR; THROMBOCYTE;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ATHEROSCLEROSIS; BLOOD COAGULATION; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; INFLAMMATION; MICE; PLATELET AGGREGATION INHIBITORS; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; RISK FACTORS; SECONDARY PREVENTION; THROMBIN; WARFARIN;

EID: 84928638030     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.02.013     Document Type: Review

References (57)

1. N.R. Goldsack, R.C. Chambers, K. Dabbagh, and G.J. Laurent Thrombin Int J Biochem Cell Biol 30 6 1998 641 646
2. F.C. Church, C.W. Pratt, C.M. Noyes, T. Kalayanamit, G.B. Sherrill, and R.B. Tobin Structural and functional properties of human alpha-thrombin, phosphopyridoxylated alpha-thrombin, and gamma T-thrombin. Identification of lysyl residues in alpha-thrombin that are critical for heparin and fibrin(ogen) interactions J Biol Chem 264 31 1989 18419 18425
3. H.M. Spronk, J.W. Govers-Riemslag, and H. ten Cate The blood coagulation system as a molecular machine Bioessays 25 12 2003 1220 1228
4. J.I. Borissoff, H.M. Spronk, S. Heeneman, and H. ten Cate Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res 82 3 2009 392 403
5. E.W. Davie, K. Fujikawa, and W. Kisiel The coagulation cascade: initiation, maintenance, and regulation Biochemistry 30 43 1991 10363 10370
6. S. Butenas, and K.G. Mann Blood coagulation Biochemistry (Mosc) 67 1 2002 3 12
7. B. Blomback Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis Thromb Res 83 1 1996 1 75
8. T. Dutt, and C.H. Toh The Yin-Yang of thrombin and activated protein C Br J Haematol 140 5 2008 505 515
9. D.A. Lane, H. Philippou, and J.A. Huntington Directing thrombin Blood 106 8 2005 2605 2612
10. H. Ishihara, A.J. Connolly, D. Zeng, M.L. Kahn, Y.W. Zheng, and C. Timmons Protease-activated receptor 3 is a second thrombin receptor in humans Nature 386 6624 1997 502 506
11. J.L. Strande, A. Hsu, J. Su, X. Fu, G.J. Gross, and J.E. Baker Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling J Pharmacol Exp Ther 324 3 2008 1045 1054
12. P. Vidwan, A. Pathak, S. Sheth, J. Huang, D.M. Monroe, and G.A. Stouffer Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells Arterioscler Thromb Vasc Biol 30 12 2010 2587 2596
13. M. Popovic, K. Smiljanic, B. Dobutovic, T. Syrovets, T. Simmet, and E.R. Isenovic Thrombin and vascular inflammation Mol Cell Biochem 359 1-2 2012 301 313
14. K. Hirano The roles of proteinase-activated receptors in the vascular physiology and pathophysiology Arterioscler Thromb Vasc Biol 27 1 2007 27 36
15. H.L. Hsieh, W.H. Tung, C.Y. Wu, H.H. Wang, C.C. Lin, and T.S. Wang Thrombin induces EGF receptor expression and cell proliferation via a PKC(delta)/c-Src-dependent pathway in vascular smooth muscle cells Arterioscler Thromb Vasc Biol 29 10 2009 1594 1601
16. I. Furuhashi, K. Abe, T. Sato, and H. Inoue Thrombin-stimulated proliferation of cultured human synovial fibroblasts through proteolytic activation of proteinase-activated receptor-1 J Pharmacol Sci 108 1 2008 104 111
17. P.J. Kell, M.H. Creer, K.N. Crown, K. Wirsig, and J. McHowat Inhibition of platelet-activating factor (PAF) acetylhydrolase by methyl arachidonyl fluorophosphonate potentiates PAF synthesis in thrombin-stimulated human coronary artery endothelial cells J Pharmacol Exp Ther 307 3 2003 1163 1170
18. T. Tokunou, T. Ichiki, K. Takeda, Y. Funakoshi, N. Iino, and H. Shimokawa Thrombin induces interleukin-6 expression through the cAMP response element in vascular smooth muscle cells Arterioscler Thromb Vasc Biol 21 11 2001 1759 1763
19. S.A. Huber, P. Sakkinen, D. Conze, N. Hardin, and R. Tracy Interleukin-6 exacerbates early atherosclerosis in mice Arterioscler Thromb Vasc Biol 19 10 1999 2364 2367
20. C. Zhang, T.W. Hein, W. Wang, M.W. Miller, T.W. Fossum, and M.M. McDonald Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles Hypertension 44 6 2004 935 943
21. M. Caunt, Y.Q. Huang, P.C. Brooks, and S. Karpatkin Thrombin induces neoangiogenesis in the chick chorioallantoic membrane J Thromb Haemost 1 10 2003 2097 2102
22. R. Virmani, F.D. Kolodgie, A.P. Burke, A.V. Finn, H.K. Gold, and T.N. Tulenko Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage Arterioscler Thromb Vasc Biol 25 10 2005 2054 2061
23. F. Bea, J. Kreuzer, M. Preusch, S. Schaab, B. Isermann, and M.E. Rosenfeld Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 26 12 2006 2787 2792
24. H. Ten Cate Thrombin generation in clinical conditions Thromb Res 129 3 2012 367 370
25. H.J. Beijers, I. Ferreira, H.M. Spronk, B. Bravenboer, J.M. Dekker, and G. Nijpels Body composition as determinant of thrombin generation in plasma: the Hoorn study Arterioscler Thromb Vasc Biol 30 12 2010 2639 2647
26. A. Tripodi, A. Branchi, V. Chantarangkul, M. Clerici, G. Merati, and A. Artoni Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay J Thromb Thrombolysis 31 2 2011 165 172
27. M. Cushman, B.M. Psaty, E. Macy, E.G. Bovill, E.S. Cornell, and L.H. Kuller Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease Arterioscler Thromb Vasc Biol 16 9 1996 1163 1169
28. J.I. Borissoff, I.A. Joosen, M.O. Versteylen, H.M. Spronk, H. ten Cate, and L. Hofstra Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis JACC Cardiovasc Imaging 5 12 2012 1201 1210
29. K. Aihara, H. Azuma, N. Takamori, Y. Kanagawa, M. Akaike, and M. Fujimura Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals Circulation 109 22 2004 2761 2765
30. J.A. Paramo, J. Orbe, O. Beloqui, A. Benito, I. Colina, and E. Martinez-Vila Prothrombin fragment 1 + 2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease Stroke 35 5 2004 1085 1089
31. A.T. With Noto, E.B. Mathiesen, B. Osterud, J. Amiral, A.M. Vissac, and J.B. Hansen Increased thrombin generation in persons with echogenic carotid plaques Thromb Haemost 99 3 2008 602 608
32. A. Komocsi, A. Vorobcsuk, D. Kehl, and D. Aradi Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials Arch Intern Med 172 20 2012 1537 1545
33. L.K. Jennings Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis Thromb Haemost 102 2 2009 248 257
34. J. Orbe, M. Zudaire, R. Serrano, I. Coma-Canella, S. Martinez de Sizarrondo, and J.A. Rodriguez Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test Thromb Haemost 99 2 2008 382 387
35. P.A. Merlini, K.A. Bauer, L. Oltrona, D. Ardissino, M. Cattaneo, and C. Belli Persistent activation of coagulation mechanism in unstable angina and myocardial infarction Circulation 90 1 1994 61 68
36. M. Smid, A.W. Dielis, M. Winkens, H.M. Spronk, R. van Oerle, and K. Hamulyak Thrombin generation in patients with a first acute myocardial infarction J Thromb Haemost 9 3 2011 450 456
37. F. Andreotti, L. Testa, G.G. Biondi-Zoccai, and F. Crea Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Eur Heart J 27 5 2006 519 526
38. M.B. Rothberg, C. Celestin, L.D. Fiore, E. Lawler, and J.R. Cook Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit Ann Intern Med 143 4 2005 241 250
39. L. Wallentin, R.G. Wilcox, W.D. Weaver, H. Emanuelsson, A. Goodvin, and P. Nystrom Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 9386 2003 789 797
40. O. Sergent, K. Ekroos, L. Lefeuvre-Orfila, M. Rissel, G.B. Forsberg, and J. Oscarsson Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes Toxicol In Vitro 23 7 2009 1305 1310
41. P.G. Steg, S.R. Mehta, J.W. Jukema, G.Y. Lip, C.M. Gibson, and F. Kovar RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome Eur Heart J 32 20 2011 2541 2554
42. J.H. Alexander, R.C. Becker, D.L. Bhatt, F. Cools, F. Crea, and M. Dellborg Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 22 2009 2877 2885
43. J.L. Mega, E. Braunwald, S. Mohanavelu, P. Burton, R. Poulter, and F. Misselwitz Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 9683 2009 29 38
44. J. Oldgren, A. Budaj, C.B. Granger, Y. Khder, J. Roberts, and A. Siegbahn Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 22 2011 2781 2789
45. J.L. Mega, E. Braunwald, S.D. Wiviott, J.P. Bassand, D.L. Bhatt, and C. Bode Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 1 2012 9 19
46. J.H. Alexander, R.D. Lopes, S. James, R. Kilaru, Y. He, and P. Mohan Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 8 2011 699 708
47. R. Wallin, and S.M. Hutson Warfarin and the vitamin K-dependent gamma-carboxylation system Trends Mol Med 10 7 2004 299 302
48. P.P. Singh, M. Singh, U. Bedi, J. Molnar, R. Arora, and S. Khosla Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation Ther Adv Cardiovasc Dis 5 1 2011 23 31
49. H.J. Zhao, Z.T. Zheng, Z.H. Wang, S.H. Li, Y. Zhang, and M. Zhong «Triple therapy» rather than «triple threat»: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment Chest 139 2 2011 260 270
50. W.J.M. Dewilde, T. Oirbans, F.W.A. Verheugt, J.C. Kelder, B.J.G.L. De Smet, and J-P. Herrman Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised randomised, controlled trial. Lancet 381 9872 2011 260 270
51. W.J. Dewilde, T. Oirbans, F.W. Verheugt, J.C. Kelder, B.J. De Smet, and J.P. Herrman Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 9872 2013 1107 1115
52. National Institutes of Health [cited 2013 December 19]. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00776633?term=triple+therapy+AND+kastrati&rank=1
53. J.S. Paikin, D.S. Wright, M.A. Crowther, S.R. Mehta, and J.W. Eikelboom Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Stents Circulation 121 18 2010 2067 2070
54. M. Moser, C.B. Olivier, and C. Bode Triple antithrombotic therapy in cardiac patients: more questions than answers Eur Heart J 35 4 2014 216 223
55. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
56. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
57. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 981 992